Contribute Try STAT+ Today

WASHINGTON — As the coronavirus pandemic disrupts global supply chains, lawmakers are increasingly calling on drug makers to exclusively manufacture medicines in the United States. But for a large swath of the pharmaceutical industry, that’s an existential threat.

Already, lawmakers have saddled drug makers with extra paperwork and mandated that they develop and submit to the Food and Drug Administration “contingency plans” when they run low on certain critical drugs. But some lawmakers want to go much further: They are contemplating previously unheard of steps, like virtually mandating drug makers stop sourcing any of the ingredients that go into medicines from China, or requiring consumer warnings on drugs made there. Since the pandemic began, lawmakers have introduced roughly 20 bills aimed at overhauling the drug supply chain.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Nick, I would think next up might be some discussion about restoring patents based on US R&D back to US shores too, instead of off-shoring them to foreign subsidiaries in low-tax havens, then licensing back manufacturing and distribution rights. The 2017 tax bill made that less important, but a few tens of billions here and there eventually add up.

    Any discussion of that in your conversations with folks on the Hill?

Comments are closed.